The carcinogenic properties of 3-methylcholanthrene, covalently (by means of bisdiazotized benzidine) bound to protein, were studied in experiments on mice. It was shown that binding with protein in this way does not abolish carcinogenic activity: Sarcomas developed rapidly at the sites of subcutaneous injection of the conjugate. For this reason, immunization of animals with conjugated 3-methyl-cholanthrene-protein antigen in order to obtain antibodies specifically binding the carcinogen is difficult.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
I. E. Kovalev, Khim.-Farmats. Zh., No. 12, 3 (1977).
I. E. Kovalev, V. V. Shaidrov, and O. Yu. Polevaya, Farmakol. Toksikol., No. 2, 221 (1976).
O. Yu. Polevaya and I. E. Kovalev, Khim. Farmats. Zh., No. 2, 8 (1978).
L. M. Shabad and T. A. Korosteleva, Byull. Éksp. Biol., Med., No. 3, 28 (1940).
W. R. Franks and H. J. Creech, Am. J. Cancer,35, 203 (1939).
E. B. Peck, Cancer Res.,31, 1550 (1971).
About this article
Cite this article
Kovalev, I.E., Kolesnichenko, T.S. & Polevaya, O.Y. Induction of malignant tumors in mice by methylcholanthrene bound covalently with bovine serum albumin. Bull Exp Biol Med 89, 338–339 (1980). https://doi.org/10.1007/BF00834246
- carcinogen-protein conjugate